Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Radiology. 2022 Apr 12;304(1):228–237. doi: 10.1148/radiol.212426

Table 3:

Median Overall Survival in All BCLC and Reassigned Treatment Stages

Median Overall Survival (mo)
Stage Overall ETV <65 cm3 ETV ≥65 cm3 ETB <4% ETB ≥4%
BCLC B (n = 123) 24.3 (21.4, 32.9) 32.9 (26.6, NA) 21.1 (12.1, 25.1) 32.9 (23.5, NA) 21.7 (12.1, 28.4)
BCLC C (n = 371) 11.9 (10.5, 14.8) 25.4 (20.3, 34.1) 8.4 (6.1, 11.2) 25.4 (20.2, 34.1) 8.4(6.1, 11.4)
BCLC B + C (n = 494) 15.0 (12.3, 17.2) 28.4 (23.5, 38.9) 10.5 (8.4, 11.9) 26.7 (22, 36.8) 10.6 (8.1, 12)
BCLC Bn (n = 213) NA 25.1 (21.8, 29.7) ... 24.3 (21.7, 29.7) ...
BCLC Cn (n = 281) NA ... 8.4 (6.1, 11.2) ... 8.4(6.1, 11.4)

Note.—BCLC = Barcelona Clinic Liver Cancer, BCLC Bn = patients with BCLC stage B plus those with BCLC stage C with low tumor burden (ETV <65 cm3 or ETB <4%), BCLC Cn = remaining patients with BCLC stage C with high tumor burden (ETV ≥65 cm3 or ETB ≥4%), ETB = enhancing tumor burden, ETV = enhancing tumor volume, NA = not applicable.